RxDoctor Payments Data

Robert Hannahan, MD

Anesthesiology · Enterprise, ALNPI 1720074818

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,484 of the $4,711 with a category attached, or 73.9%. 16 manufacturers reported payments, led by Nevro Corp. at 43.5% of the total. Reporting peaked in 2019 at $1,789 and has fallen 82.1% since, to $320 in 2025. Among anesthesiology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,711in general payments, 2019–2025

Across 122 payments — averaging $38.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$2K
  • Boston Scientific$650
  • Nalu Medical, Inc.$646
  • Stimwave Technologies Incorporated$364
  • Curonix LLC$235
  • Vertos Medical, Inc.$192
  • plus $575 from 10 others

What the payments were for

  • Travel & lodging$1,16125%
  • Food & beverage$3,48474%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,711 in reported general payments places this provider in the 95th percentile of 484 anesthesiology providers in Alabama.

See all anesthesiology providers in Alabama

Medicare billing

Part B allowed, 2024
$236,601
Medicare patients
204
Services billed
2,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZtlidoLidocaine22$22,387
Aimovig AutoinjectorErenumab-Aooe15$11,010
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen343$7,270
Gabapentin138$2,773
Ibuprofen106$1,790
Lidocaine20$1,707
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen75$1,662
Pregabalin52$1,661
Famotidine102$1,514
Methocarbamol43$839
Tizanidine Hcl42$827
Esomeprazole Magnesium14$756
Amitriptyline Hcl54$631
Tramadol Hcl96$534
Oxycodone Hcl33$486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$153$22,38722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 484 anesthesiology providers in Alabama.

Other anesthesiology in Enterprise

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →